# NCT05675410 (NCT05675410)

> A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05675410
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions: Biospecimen Collection; Bleomycin Sulfate; Brentuximab Vedotin; Computed Tomography; Cyclophosphamide; Dacarbazine; Doxorubicin Hydrochloride; Etoposide; Etoposide Phosphate; Fludeoxyglucose F-18; Involved-site Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Prednisolone; Prednisone; Procarbazine Hydrochloride; Questionnaire Administration; Vinblastine Sulfate; Vincristine Sulfate
- Enrollment: 1875
- Primary outcome: Progression-free survival (PFS) in rapid early responder (RER) patients
- Primary outcome: PFS in slow-early responder (SER) patients

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05675410